Worries and concerns in a large unselected cohort of patients with Crohn's disease

被引:79
|
作者
Stjernman, Henrik [1 ]
Tysk, Curt [2 ,3 ]
Almer, Sven [4 ]
Strom, Magnus [4 ]
Hjortswang, Henrik [4 ]
机构
[1] Cty Hosp Ryhov, Dept Med, Div Gastroenterol, S-55185 Jonkoping, Sweden
[2] Orebro Univ Hosp, Dept Med, Div Gastroenterol, Orebro, Sweden
[3] Univ Orebro, Sch Hlth & Med Sci, Orebro, Sweden
[4] Linkoping Univ Hosp, Dept Clin & Expt Med, Div Gastroenterol & Hepatol, S-58185 Linkoping, Sweden
关键词
QUALITY-OF-LIFE; INFLAMMATORY-BOWEL-DISEASE; SHORT HEALTH SCALE; SUBJECTIVE HEALTH; SWEDISH PATIENTS; CLINICAL-TRIALS; QUESTIONNAIRE; EFFICACY; VALIDITY; VERSION;
D O I
10.3109/00365521003734141
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective. Disease-related worries constitute an important dimension of patient-reported perception of health status in inflammatory bowel disease (IBD). The Rating Form of IBD Patient Concerns (RFIPC) questionnaire is purported to measure IBD-related worries. This study evaluated the psychometric properties of a Swedish translation of RFIPC in an unselected population of Crohn's disease (CD) patients. The degree and nature of the worries were characterized and predictive factors for outcome of RFIPC and underlying dimensions were identified. Material and Methods. The RFIPC was completed by 447 CD patients in conjunction with regular visits. A physician global assessment of disease activity and four other health-related quality of life (HRQL) questionnaires were used for construct validity. Reliability and responsiveness were evaluated with follow-up visits. Underlying dimension and predictive factors were identified with factor analysis and multiple linear regression analysis. Results. Test-retest reliability was 0.90, correlation with corresponding HRQL measures 0.60-0.80 and responsiveness ratio 0.84. Median RFIPC sum score was lower than in previous studies. Top three concerns were ostomy, energy level and bowel control. Four dimensions were identified in descending order of concern: disease-related complications, daily-life achievements, intimacy, and stigmatization. Predictors of RFIPC score were disease activity, gender, and BMI (p < 0.001-0.008). Conclusions. The Swedish version of RFIPC exhibited an adequate psychometric performance in CD patients, but was less sensitive to change in disease activity. The patients were more concerned about complications and achievement than intimacy and stigmatization. The strongest predictors of more worry were active disease, female gender and higher BMI.
引用
收藏
页码:696 / 706
页数:11
相关论文
共 50 条
  • [31] Results of Minimally Invasive HVAD Insertion in a Large Cohort of Unselected Patients
    Kaczorowski, D. J.
    Kon, Z. N.
    Sorensen, E. N.
    Pham, S. M.
    Pasrija, C.
    Dees, L. M.
    Madathil, R. J.
    Ton, V.
    Feller, E. D.
    Griffith, B. P.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S366 - S367
  • [32] Pregnancy and Crohn's disease: concerns and assurance of medical therapy
    Chowdhury, Reezwana
    Kane, Sunanda, V
    [J]. GASTROENTEROLOGY REPORT, 2022, 10
  • [33] Patients' Perspectives, Experiences, and Concerns With Crohn's Perianal Fistulae: Qualitative Insights From Crohn's Disease Social Media Platforms
    Khalil, Carine
    Van Deen, Welmoed
    Dupuy, Taylor
    Syal, Gaurav
    Cazzetta, Susan E.
    Nazarey, Pradeep P.
    Almario, Christopher V.
    Spiegel, Brennan
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1364 - S1364
  • [34] Antineutrophil Cytoplasmic Antibodies Testing in a Large Cohort of Unselected Greek Patients
    Tsiveriotis, Konstantinos
    Tsirogianni, Alexandra
    Pipi, Elena
    Soufleros, Konstantinos
    Papasteriades, Chryssa
    [J]. AUTOIMMUNE DISEASES, 2011, 2011
  • [35] Genotypic Overlap Between Crohn's Disease (CD) and Ulcerative Colitis (UC) in a Large Cohort of Patients With Inflammatory Bowel Disease (IBD)
    Waterman, Matti
    Stempak, Joanne M.
    Kabakchiev, Boyko
    Xu, Wei
    Griffiths, Anne M.
    Greenberg, Gordon R.
    Steinhart, Hillary
    Silverberg, Mark S.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S678 - S678
  • [36] Disability in newly diagnosed patients with Crohn′s Disease: initial results from the prospective CROCO (Crohn′s Disease Cohort) Study
    Tinoco da Silva Torres, J.
    Ellul, P.
    Vieujean, S.
    Ordas, I.
    Burisch, J.
    Mocanu, I.
    Duricova, D.
    Rodriguez-Lago, I.
    Buisson, A.
    Goldis, A.
    Hernandez, V.
    Arebi, N.
    Kaimakliotis, I.
    Nachury, M.
    Fumery, M.
    Allocca, M.
    Pedersen, N.
    Barberio, B.
    Shaji, S.
    Guedes, A.
    Ribeiro, R.
    Ungaro, R.
    Lambert, J.
    Colombel, J. F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 443 - 444
  • [37] Is there a birth cohort effect for Crohn's disease?
    Morris, DL
    Leon, DA
    Kyle, J
    Montgomery, SM
    Pounder, RE
    Wakefield, AJ
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A1359 - A1359
  • [38] Clinical Experience With Adalimumab in a Multicenter Swiss Cohort of Patients With Crohn's Disease
    Stelle, Marc
    Nichita, Cristina
    Vavricka, Stephane
    Rogler, Gerhard
    de Saussure, Philippe
    Straumann, Alex
    Michetti, Pierre
    [J]. SWISS MEDICAL WEEKLY, 2009, 139 (35-36) : 12S - 12S
  • [39] A retrospective cohort study on vedolizumab trough levels in Crohn's disease patients
    Pokryszka, J.
    Stadlmann, M.
    Primas, C.
    Gerold, N.
    Reinisch, S.
    Novacek, G.
    Reinisch, W.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 919 - 919
  • [40] Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients
    Chapuis-Biron, Constance
    Bourrier, Anne
    Nachury, Maria
    Nancey, Stephane
    Bouhnik, Yoram
    Serrero, Melanie
    Armengol-Debeir, Laura
    Buisson, Anthony
    Tran-Minh, My-Linh
    Zallot, Camille
    Fumery, Mathurin
    Bouguen, Guillaume
    Abitbol, Vered
    Viennot, Stephanie
    Chanteloup, Elise
    Rajca, Sylvie
    Dib, Nina
    Parmentier, Anne-Laure
    Peyrin-Biroulet, Laurent
    Vuitton, Lucine
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (07) : 719 - 727